CHEK2 and cancer: In summary, the analyses provided strong or moderate evidence supporting the alternative hypothesis (compared with H0) predicting a lower prevalence of excellent response, NED in final follow-up, tumor size ≤10 mm (compared with >10 mm and ≤20 mm), classic cancer subtype (compared with other aggressive) in patients with higher CHK2 expression, lower prevalence of absence of vascular invasion, and age <55 years, in patients with deletion of the TP53 gene copy and positive p53 together with deletion of the TP53 gene copy.